Immune responses to recall antigens
| Patient . | Before rituximab treatment . | After rituximab treatment . | ||||||
|---|---|---|---|---|---|---|---|---|
| PV1 . | PV2 . | PV3 . | TT . | PV1 . | PV2 . | PV3 . | TT . | |
| A | 32* (9) | 128 (9) | 64 (7) | — | — | — | — | 0.9 (2) |
| F | 2 (4.5) | 8 (6.5) | 256 (8.5) | — | — | — | — | 1.1 (4) |
| I | 0.5 (1) | 2 (4.5) | 4 (3) | — | — | — | — | 0.7 (1) |
| K | 16 (8) | 32 (8) | 256 (8.5) | — | — | — | — | 4.1 (8.5) |
| B | — | — | — | 2.8 (6) | 2 (4.5) | 1 (2.5) | 1 (1.5) | — |
| C | — | — | — | 4.1 (8.5) | 4 (7) | 8 (6.5) | 32 (6) | — |
| D | — | — | — | 1 (3) | 2 (4.5) | 0.5 (1) | 1 (1.5) | — |
| G | — | — | — | 3.8 (7) | 2 (4.5) | 1 (2.5) | 16 (5) | — |
| J | — | — | — | 1.9 (5) | 1 (2) | 2 (4.5) | 8 (4) | — |
| Patient . | Before rituximab treatment . | After rituximab treatment . | ||||||
|---|---|---|---|---|---|---|---|---|
| PV1 . | PV2 . | PV3 . | TT . | PV1 . | PV2 . | PV3 . | TT . | |
| A | 32* (9) | 128 (9) | 64 (7) | — | — | — | — | 0.9 (2) |
| F | 2 (4.5) | 8 (6.5) | 256 (8.5) | — | — | — | — | 1.1 (4) |
| I | 0.5 (1) | 2 (4.5) | 4 (3) | — | — | — | — | 0.7 (1) |
| K | 16 (8) | 32 (8) | 256 (8.5) | — | — | — | — | 4.1 (8.5) |
| B | — | — | — | 2.8 (6) | 2 (4.5) | 1 (2.5) | 1 (1.5) | — |
| C | — | — | — | 4.1 (8.5) | 4 (7) | 8 (6.5) | 32 (6) | — |
| D | — | — | — | 1 (3) | 2 (4.5) | 0.5 (1) | 1 (1.5) | — |
| G | — | — | — | 3.8 (7) | 2 (4.5) | 1 (2.5) | 16 (5) | — |
| J | — | — | — | 1.9 (5) | 1 (2) | 2 (4.5) | 8 (4) | — |
Ratios to PV1, PV2, and PV3 are listed separately.
Antibody responses to TT, PV1, PV2, and PV3 in the 9 patients immunized before and after rituximab treatment are expressed as ratios of post- and preimmunization titers. Ratios to TT, PV1, PV2, and PV3 were ranked. Ranks are depicted in parentheses. Paired ranks, consisting of the rank obtained by each patient before andafter rituximab treatment, were analyzed by Wilcoxon signed rank test.